At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Gemcitabine +1 moredrug
Likely dose
Gemcitabine 900 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
In Brief
A Phase 2 clinical trial evaluating Gemcitabine and Cisplatin for Endometrial Cancer. Completed, enrolled 21 participants across 3 sites.
Detailed Summary
Primary Objective: * To estimate the antitumor activity of the combination of gemcitabine and cisplatin in patients with advanced (stage III or IV) or recurrent endometrial cancer. Secondary Objective: * To determine the nature and degree of toxicity of the combination of gemcitabine and cisplatin in this cohort of patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2004
First PostedOct 2006
Primary CompletionNov 2013
TodayJul 2026
First PostedOct 16, 2006
Enrollment StartAug 1, 2004
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 19.7 years ago
Interventions
Gemcitabinedrug
900 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.
Cisplatindrug
30 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.